These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37941916)

  • 1. Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.
    Huang H; Liu J; Yang L; Yan Y; Chen M; Li B; Xu Z; Qin T; Qu S; Wang L; Huang G; Chen Y; Xiao Z
    Blood Sci; 2023 Oct; 5(4):258-268. PubMed ID: 37941916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
    Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in
    Bartalucci N; Calabresi L; Balliu M; Martinelli S; Rossi MC; Villeval JL; Annunziato F; Guglielmelli P; Vannucchi AM
    Oncotarget; 2017 Nov; 8(57):96710-96724. PubMed ID: 29228564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
    Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
    J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
    Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
    Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
    Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
    Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micheliolide inhibits gastric cancer growth
    Tang X; Ding Q; Chen C; Chen F; Zhou X; Hong CJ; Pan W
    Pharmazie; 2019 Mar; 74(3):175-178. PubMed ID: 30961685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
    Yan D; Jobe F; Hutchison RE; Mohi G
    Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34
    Chen Y; Zhao H; Luo J; Liao Y; Tan K; Hu G
    Oncol Lett; 2021 May; 21(5):351. PubMed ID: 33747208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK6 Is a Therapeutic Target in Myelofibrosis.
    Dutta A; Nath D; Yang Y; Le BT; Mohi G
    Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
    Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
    Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
    Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F
    De Marinis E; Ceccherelli A; Quattrocchi A; Leboffe L; Polticelli F; Nervi C; Ascenzi P
    Sci Rep; 2019 Nov; 9(1):16379. PubMed ID: 31704999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.